Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,730 across all filing types
Latest filing 2025-05-09 Fund Information / Fact…
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
114年4月營業收入
Fund Information / Factsheet Classification · 90% confidence The document is a summary report of monthly and cumulative net operating revenue figures for a company named 美時, presented in a tabular format with explanations about accounting standards and reporting practices. It contains financial data for a specific month and year (April 114 in the Taiwanese calendar, corresponding to 2025), including comparisons to the previous year. The document is short (780 characters) and does not contain comprehensive financial statements or detailed analysis typical of an Interim/Quarterly Report (IR) or Annual Report (10-K). It is more of a brief financial summary or factsheet. Given the concise nature and focus on key financial figures, this fits best with the Fund Information / Factsheet (FS) category, which is for brief summaries of key company facts and financials.
2025-05-09 Chinese
114年04月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document consists of detailed tables listing shareholdings of company insiders, including directors, general managers, deputy general managers, and major shareholders. It shows changes in shareholdings, including increases and decreases, and categorizes shares by type and ownership status. The content is focused on insider share transactions and holdings rather than financial results, management changes, or regulatory announcements. There is no indication of a full financial report, earnings release, or meeting materials. The document is a report of personal share transactions and holdings by company directors and executives, fitting the definition of Director's Dealing (DIRS). The document length is substantial and contains detailed data, not a brief announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA).
2025-05-09 Chinese
114年04月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings by insiders, including directors, supervisors, and senior management, showing their current and pledged shares. It lists individual names, titles, and share counts, focusing on insider shareholdings and related disclosures. There is no indication of financial results, earnings, management discussion, or regulatory certifications. The content aligns with reporting of insider share transactions or holdings by company directors and executives. Given the nature of the data and the focus on insider holdings, the document fits best under the category of Director's Dealing (DIRS). The document length is under 5,000 characters, but it is not a mere announcement or report publication notice; it contains substantive insider shareholding data. Therefore, the classification is DIRS with high confidence.
2025-05-09 Chinese
公告本公司114年第一季合併財務報告董事會召開日期為 114年05月09日
Regulatory Filings Classification · 95% confidence The document is a short announcement (543 characters) from a company (1795 美時) stating the date of the board meeting to be held on 114/05/09 to discuss the consolidated financial report for the first quarter of the year 114. It does not contain the financial report itself but only announces the upcoming board meeting and the expected report to be discussed. According to the 'MENU VS MEAL' rule, this is an announcement about a report, not the report itself. Therefore, it should be classified as a Regulatory Filing (RNS), which is the fallback category for such announcements that do not contain substantive financial data or the report itself.
2025-04-30 Chinese
公告本公司董事會決議召開114年股東常會(增列議案)
AGM Information Classification · 95% confidence The document is a public announcement from a listed company (1795 美時) regarding the board resolution to convene the 114th Annual General Meeting (AGM). It includes details such as the date and location of the AGM, agenda items including reports on the previous fiscal year (113年度營業報告及財務報告), dividend distribution, amendments to company articles, capital increase proposals, election of a director, and other shareholder meeting matters. The document is short (1073 characters) and primarily serves as a notice of the AGM and its agenda rather than the full AGM materials or reports themselves. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or announcements related to it.
2025-04-28 Chinese
公告董事會決議辦理國內現金增資發行普通股及/或現金增資 發行普通股參與發行海外存託憑證及/或私募方式發行普通股及/ 或私募方式發行可轉換公司債案
Capital/Financing Update Classification · 100% confidence The document is a company announcement regarding a board resolution to conduct a domestic cash capital increase by issuing common shares and/or convertible bonds, including private placements and overseas depositary receipts. It details the issuance amount, terms, and intended use of funds. The document is short (1079 characters) and focuses on financing activities and capital structure changes. It is not a full financial report, audit, or earnings release, nor is it a meeting presentation or voting result. The content fits the definition of a Capital/Financing Update (CAP).
2025-04-28 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.